全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Long-Term Persistent Absolute Insulin Secretion Deficiency in Diabetes Induced by Immune Checkpoint Inhibitors

DOI: 10.4236/ojemd.2023.1312017, PP. 227-233

Keywords: Immune Checkpoint Inhibitors, Nivolumab, Ipilimumab, Fulminant Diabetes, Insulin-Requiring Diabetes

Full-Text   Cite this paper   Add to My Lib

Abstract:

Immune checkpoint inhibitors are today an immense hope in the management of cancers. However, since their widespread use, many cases of insulin-requiring diabetes appearing suddenly, as fulminant diabetes have been reported. Here, we describe 4 cases that occurred at different times after the beginning of immune checkpoint inhibitor therapy with Nivolumab alone or associated with Ipilimumab. There are 3 cases of newly diagnosed diabetes and 1 case of known type 2 diabetes formerly quite well balanced with Metformin. The clinical and biological characteristics of these patients are quite similar. They were all insulin-requiring at the discovery of diabetes and remained so throughout their follow-up. This type of diabetes which looks like type 1 diabetes seems rather to be a new entity.

References

[1]  Robert, C. and Mateus, C. (2014) Mélanome—Thérapeutique par les médications : anticorps anti-CTLA-4 et anti-PD1. Bulletin de l’Académie Nationale de Médecine, 198, 297-308.
https://doi.org/10.1016/S0001-4079(19)31343-3
[2]  Wang, P.-F., Chen, Y., Song, S.-Y., Wang, T.-J., Ji, W.-J., Li, S.-W., Liu, N. and Yan, C.-X. (2017) Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Frontiers in Pharmacology, 8, 730.
https://doi.org/10.3389/fphar.2017.00730
[3]  Sznol, M., Postow, M.A., Davies, M.J., Pavlick, A.C., Plimack, E.R., Shaheen, M., Veloski, C. and Robert, C. (2017) Endocrine-Related Adverse Events Associated with Immune Checkpoint Blockade and Expert Insights on Their Management. Cancer Treatment Reviews, 58, 70-76.
https://doi.org/10.1016/j.ctrv.2017.06.002
[4]  Kotwal, A., Haddox, C., Block, M. and Kudva, Y.C. (2019) Immune Checkpoint Inhibitors: An Emerging Cause of Insulin-Dependent Diabetes. BMJ Open Diabetes Research & Care, 7, e000591.
https://doi.org/10.1136/bmjdrc-2018-000591
[5]  Marchand, L., Disse, E., Dalle, S., Reffet, S., Vouillarmet, J., Fabien, N., Thivolet, C. and Anceau, C.C. (2019) The Multifaceted Nature of Diabetes Mellitus Induced by Checkpoint Inhibitors. Acta Diabetologica, 56, 1239-1245.
https://doi.org/10.1007/s00592-019-01402-w
[6]  Quandt, Z., Young, A. and Anderson, M. (2020) Immune Checkpoint Inhibitor Diabetes Mellitus: A Novel form of Autoimmune Diabetes. Clinical and Experimental Immunology, 200, 131-140.
https://doi.org/10.1111/cei.13424
[7]  Wright, J.J., Salem, J.E., Johnson, D.B., Lebrun-Vignes, B., Stamatouli, A., Thomas, J.W., Herold, K.C., Moslehi, J. and Powers, A.C. (2018) Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes Care, 41, e150-e151.
https://doi.org/10.2337/dc18-1465
[8]  Gauci, M.L., Laly, P., Vidal-Trecan, T., Baroudjian, B., Gottlieb, J., Madjlessi-Ezra, N., Meda, L.D., Madelaine-Chambrin, I., Bagot, M., Basset-Seguin, N., Pages, C., Mourah, S., Boudou, P., Lebbé, C. and Gautier, J.F. (2017) Autoimmune Diabetes Induced by PD-1 Inhibitor—Retrospective Analysis and Pathogenesis: A Case Report and Literature Review. Cancer Immunology, Immunotherapy, 66, 1399-1410.
https://doi.org/10.1007/s00262-017-2033-8
[9]  Imagawa, A., Hanafusa, T., Miyagawa, J. and Matsuzawa, Y. (2000) A Novel Subtype of Type 1 Diabetes Mellitus Characterized by a Rapid Onset and an Absence of Diabetes-Related Antibodies. The New England Journal of Medicine, 342, 301-307.
https://doi.org/10.1056/NEJM200002033420501
[10]  Hanafusa, T. (2020) Fulminant Type 1 Diabetes: 20 Years of Discovery and Development. Diabetology International, 11, 310-314.
https://doi.org/10.1007/s13340-020-00458-2
[11]  Preiato, V.L., Salvagni, S., Ricci, C., Ardizzoni, A., Pagotto, U. and Pelusi, C. (2021) Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: Type 1 Diabetes Variant or New Clinical Entity? Review of the Literature. Reviews in Endocrine and Metabolic Disorders, 22, 337-349.
https://doi.org/10.1007/s11154-020-09618-w
[12]  Stamatouli, A.M., Quandt, Z., Perdigoto, A.L., Clark, P.L., Kluger, H., Weiss, S.A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., Lee, J., Bluestone, J.A., Anderson, M. and Herold, K.C. (2018) Collateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors. Diabetes, 67, 1471-1480.
https://doi.org/10.2337/dbi18-0002
[13]  Kapke, J., Shaheen, Z., Kilari, D., Knudson, P. and Wong, S. (2017) Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of Literature and Optimal Management. Case Reports in Oncology, 10, 897-909.
https://doi.org/10.1159/000480634
[14]  Tsang, V.H.M., McGrath, R.T., Clifton-Bligh, R.J., Scolyer, R.A., Jakrot, V., Guminski, A.D., Long, G.V. and Menzies, A.M. (2019) Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 104, 5499-5506.
https://doi.org/10.1210/jc.2019-00423

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133